4 results about "Sarafloxacin" patented technology

The application discloses a rapid detection method for fluoroquinolone drug residues based on a one-antigen two-monoclonal antibody. The application discloses a monoclonal antibody NOR McAb and a monoclonal antibody SAR McAb respectively against the fluoroquinolone drugs norfloxacin NOR and sarafloxacin SAR, a kit containing the monoclonal antibody NOR McAb and the monoclonal antibody SAR McAb, a method for detecting the fluoroquinolone drugs, and application of the monoclonal antibody NOR McAb and the monoclonal antibody SAR McAb and the kit in detection of the fluoroquinolone drugs. The application is based on a coating agent (NOR-1-BSA) and the monoclonal antibody against sarafloxacin and norfloxacin, establishes an indirect competitive ELISA method and a competitive lanthanide fluorescence microsphere lateral flow immunochromatography test strip (LFM-ICS) rapid detection technology for simultaneously detecting at least 13 kinds of fluoroquinolone drugs, and is simple in production and simple, convenient and efficient in detection.

The invention relates to the technical field of chemical synthesis, and discloses a sarafloxacin hydrochloride production process, which comprises: constructing a polyethylene glycol-ammonium sulfate aqueous two-phase reaction system; the method comprises the following steps: grafting a hydrophilic polymer chain on the surface of a polymer microsphere carrier to construct an immobilized enzyme with a carrier-grafting layer-enzyme molecule three-layer structure; adding the modified immobilized enzyme into a polyethylene glycol phase of an aqueous two-phase reaction system, adding a chemical catalyst into an ammonium sulfate phase, and carrying out a synergistic catalytic reaction under the action of an ultrasonic field; and after the reaction is completed, stopping ultrasonic treatment, separating a polyethylene glycol phase from an ammonium sulfate phase through phase separation, and performing extraction and crystallization treatment on the polyethylene glycol phase to obtain a sarafloxacin hydrochloride product. The invention solves the technical problems of mutual interference between enzyme catalysis and chemical catalysis, non-uniform distribution of immobilized enzyme, low interphase mass transfer efficiency, difficulty in product separation and the like in the traditional process.

The invention provides slow-release sarafloxacin hydrochloride soluble powder and a preparation method thereof, and belongs to the field of sarafloxacin preparations. The preparation method of the slow-release sarafloxacin hydrochloride soluble powder comprises the following steps: preparing composite drug-loaded particles, preparing microcapsules and carrying out post-treatment. According to the slow-release sarafloxacin hydrochloride soluble powder and the preparation method thereof, on the premise of effectively releasing medicine components, residual medicine in livestock and poultry bodies is rapidly metabolized and discharged, and residues of sarafloxacin in body tissues such as muscles and fat after livestock and poultry take the slow-release sarafloxacin hydrochloride soluble powder are reduced; stable and lasting release of the active ingredients in a target area is realized, and the bioavailability is improved; the stability of the soluble powder and sarafloxacin contained in the soluble powder is further improved, and good slow release performance can be kept after long-term storage.

This invention provides a soluble solid dosage form of sarafloxacin hydrochloride and its preparation method, belonging to the field of pharmaceutical technology. The soluble solid dosage form of sarafloxacin hydrochloride of this invention comprises the following components in parts by weight: 10 parts sarafloxacin hydrochloride, 6-15 parts soluble phosphate, 2-10 parts stabilizer, and 65-82 parts diluent; wherein the stabilizer is tetrasodium ethylenediaminetetraacetate or ethylenediaminetetraacetic acid; and the diluent is at least one selected from anhydrous glucose, sucrose, lactose, and maltodextrin. The soluble solid dosage form of sarafloxacin hydrochloride of this invention has good water solubility; even at high concentrations (5000 ppm), the solution remains relatively clear, making it less likely to cause blockage of drinking water pipelines when administered to livestock farms; furthermore, it is suitable for preparing solutions with different water qualities, and no special requirements are needed for water quality during clinical use.